Nexalin Technology, Inc. acquires PONM, Inc. for USD 1,300,000 (2026)

Deal facts

Buyer: Nexalin Technology, Inc.
Target: PONM, Inc.
Deal value: USD 1,300,000
Announced: 19 May 2026
Status: Completed
Sector: Healthcare
Country: United States
Consideration: shares

Sources

What we know

Nexalin Technology, Inc. has agreed to acquire PONM, Inc. in a strategic acquisition within the Healthcare sector. The transaction, valued at 1.3 million USD, was settled entirely through the exchange of shares. Both the acquiring entity and the target company are based in the United States, creating a domestic consolidation of assets in the medical technology space. The deal was announced on 19 May 2026, following its completion on 14 May 2026, indicating a rapid execution of the agreement between the two parties.

The consideration structure relies solely on equity, suggesting a focus on long-term alignment between the combined entities. As a strategic acquisition, this move integrates the capabilities of PONM, Inc. into the broader portfolio of Nexalin Technology, Inc. without the involvement of external debt or cash outlays. The transaction has now reached its final stage, with all necessary conditions for the transfer of ownership satisfied. The transaction is subject to regulatory approval.

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

1 update

14 May 2026CompletedClosed
Nexalin Technology, Inc. completes acquisition of PONM, Inc.
Item 1.01 Entry into a Material Definitive Agreement. Stock Purchase Agreement On May 14, 2026, Nexalin Technology, Inc. (the “Company”) entered into a Stock Purchase Agreement (the “Purchase Agreement”) with GreenLight Ventures LLC, a North Carolina limited liability company (“GLV”). Pursuant to the Purchase Agreement, the Company purchased from GLV, 100 shares (the “PONM Shares”) of common stock
Source

OpinionExit Mode editorial

We see a clear signal in the completed acquisition of PONM, Inc. by Nexalin Technology, Inc. announced on 19 May 2026. This strategic move in the healthcare sector involves a total value of 1.3 million USD, settled entirely through the issuance of shares. The deal is already closed, which removes the usual uncertainty surrounding regulatory clearance or financing conditions that often stall smaller transactions. For the SME founder watching this space, the structure is the most telling element. By choosing a pure share deal, the buyer has effectively aligned the interests of the PONM team with its own long-term trajectory without the friction of immediate cash outflows.

This approach carries specific commercial weight in the current US healthcare landscape. When a buyer offers only equity, they are betting on future growth to justify the premium, which often translates into a higher valuation multiple than a cash deal might command. However, it also shifts the risk profile. The founders of the target company are no longer just sellers; they become shareholders of the acquiring entity. This creates a direct dependency on the buyer's stock performance and governance. In a sector like healthcare, where regulatory approval for new devices or therapies can take years, this mechanism ensures the original team remains incentivised to drive the business forward post-close. It is a classic retention tool disguised as a payment method.

We believe this deal highlights a growing trend where smaller healthcare innovators are seeking partners who can offer scale without demanding immediate liquidity. The absence of cash consideration suggests the buyer is confident in its own balance sheet strength and the synergies between the two entities. For the typical founder navigating an exit today, this serves as a reminder that the form of payment is as critical as the headline price. A lower cash figure might be acceptable if the equity upside is substantial and the buyer has a proven track record of integrating similar assets.

Our view is that you should review your current cap table and ask your advisors to model the dilution impact of a share-only offer before entering serious talks. Do not wait for a term sheet to understand how much ownership you will retain if the deal is structured entirely in stock. This week, request a sensitivity analysis showing your post-deal equity stake under different valuation scenarios for the buyer.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2026 deals More strategic acquisition deals More from Nexalin Technology, Inc.All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

Not statedCompletedHealthcare

Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited

Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…

Buyer: Circle Health Holdings Limited
Target: CHC Healthcare Holdings Limited
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

11 August 2026ClearedHealthcare

Dolby Medical Home Respiratory Care Limited (Vivisol) to acquire Air Liquide Healthcare Limited’s home oxygen services business

Dolby Medical Home Respiratory Care Limited, trading as Vivisol, has agreed to acquire the home oxygen services business of Air Liquide Healthcare Limited in a strategic…

Buyer: Dolby Medical Home Respiratory Care Limited (Vivisol)
Target: Air Liquide Healthcare Limited’s home oxygen services business
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

10 August 2026Firm intentionHealthcare

RSLGH, LLC to acquire RYTHM, Inc.

RSLGH, LLC has agreed to acquire RYTHM, Inc., a healthcare company based in the United States, in a strategic acquisition valued at $109.5 million. The transaction invol…

Buyer: RSLGH, LLC
Target: RYTHM, Inc.
Deal value: USD 109,500,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

5 August 2026CompletedHealthcare

Ensysce Biosciences, Inc. to acquire Cy Biopharma, Inc.

Ensysce Biosciences, Inc. has agreed to acquire Cy Biopharma, Inc. in a strategic acquisition within the healthcare sector. The transaction was announced on 5 August 202…

Buyer: Ensysce Biosciences, Inc.
Target: Cy Biopharma, Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

31 July 2026Firm intentionHealthcare

Profusa, Inc. to acquire G3 Vision Labs Inc.

Profusa, Inc. has agreed to acquire G3 Vision Labs Inc. in a strategic acquisition within the healthcare sector. The transaction involves the exchange of shares as the p…

Buyer: Profusa, Inc.
Target: G3 Vision Labs Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

Buyer history